Adynxx (ADYX) 10-Q 10 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 04, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		50,105,392

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 2,299	$ 5,580
Accounts receivable, net	3,572	2,760
Inventory, net	2,783	2,702
Prepaid expenses and other current assets	240	735
Total current assets	8,894	11,777
Improvements and equipment, net	1,818	2,092
Intangible assets, net	26,088	28,498
Goodwill, net	11,959	11,959
Other assets	173	173
Total assets	48,932	54,499
Current Liabilities:
Accounts payable	2,689	2,612
Accrued expenses and other current liabilities	3,576	5,286
Contingent consideration, current	0	675
Senior secured term loan, net	11,966	11,541
Warrant liability	454	20
Total current liabilities	18,685	20,134
Contingent consideration, long-term	0	1,141
Deferred tax liability	755	749
Other long-term liabilities	328	385
Total liabilities	19,768	22,409
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 50,105,392 and 29,669,036 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	50	30
Additional paid-in capital	164,618	156,363
Accumulated deficit	(135,504)	(124,303)
Total stockholders' equity	29,164	32,090
Total liabilities and stockholders' equity	$ 48,932	$ 54,499

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	50,105,392	29,669,036
Common stock, shares outstanding	50,105,392	29,669,036

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue, net of returns, allowances and discounts	$ 5,522	$ 4,467	$ 10,116	$ 8,424
Cost of revenues	1,850	1,599	3,510	3,189
Gross profit	3,672	2,868	6,606	5,235
Operating expenses
Selling, general and administrative	7,278	9,189	15,018	18,930
Royalties	209	258	394	475
Research and product development	9	328	120	527
Acquisition-related	0	104	635	104
Change in fair value of contingent consideration liability	1	(9,092)	35	(8,730)
Total operating expenses	7,497	787	16,202	11,306
(Loss) income from operations	(3,825)	2,081	(9,596)	(6,071)
Other (expense) income
Interest expense	(596)	(653)	(1,169)	(1,271)
Interest income	2	7	4	15
Change in fair value of warrant liability	251	(75)	369	662
Warrant modification expense	(33)	0	(803)	0
Total other expense	(376)	(721)	(1,599)	(594)
(Loss) income from continuing operations before tax	(4,201)	1,360	(11,195)	(6,665)
Income tax expense	(3)	(3)	(6)	(6)
(Loss) income from continuing operations	(4,204)	1,357	(11,201)	(6,671)
Discontinued operations:
Income from discontinued operations, net of tax of $0 for the three and six months ended June 30, 2017 and 2016	0	504	0	850
Gain on sale of assets, net of tax of $0 for the three and six months ended June 30, 2017 and 2016	0	3,311	0	3,311
Income from discontinued operations, net of tax	0	3,815	0	4,161
Net (loss) income	$ (4,204)	$ 5,172	$ (11,201)	$ (2,510)
Net (loss) income per basic common share:
(Loss) income from continuing operations	$ (0.09)	$ 0.05	$ (0.29)	$ (0.24)
Income from discontinued operations	0	0.02	0	0.03
Gain on sale of assets	0	0.11	0	0.12
Total	0	0.13	0	0.15
Net (loss) income per basic common share	(0.09)	0.18	(0.29)	(0.09)
Net (loss) income per diluted common share:
(Loss) income from continuing operations	(0.09)	0.05	(0.29)	(0.24)
Income from discontinued operations	0	0.02	0	0.03
Gain on sale of assets	0	0.11	0	0.12
Total	0	0.13	0	0.15
Net (loss) income per diluted common share	$ (0.09)	$ 0.18	$ (0.29)	$ (0.09)
Weighted average shares used in computing net (loss) income per common share:
Basic	45,236,890	28,169,843	38,015,273	27,731,465
Diluted	45,236,890	28,568,600	38,015,273	27,731,465

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period	$ 0	$ 0	$ 0	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating Activities
Net loss	$ (11,201)	$ (2,510)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,761	2,085
Amortization of deferred lease incentive	(23)	(19)
Deferred income tax expense	6	6
Provision for doubtful accounts	75	31
Reserve for note receivable	350	0
Provision for excess and slow moving inventory	12	3
Stock-based compensation expense	918	3,080
Deferred rent	3	75
Amortization of debt issuance and discount costs	425	428
Warrant modification expense	803	0
Change in fair value of warrant liability	(369)	(662)
Fair value adjustment of contingent consideration liability	35	(8,730)
Gain on sale of assets	0	(3,311)
Changes in operating assets and liabilities:
Accounts receivable	(887)	(560)
Inventory	(93)	(601)
Prepaid expenses and other assets	494	294
Accounts payable	56	(473)
Accrued expenses and other current liabilities	(1,349)	413
Net Cash Used in Operating Activities	(7,984)	(10,451)
Investing Activities
Purchase of improvements and equipment	(79)	(484)
Issuance of note	(350)	0
Net Cash Used in Investing Activities	(429)	(484)
Financing Activities
Contingent purchase price payments	(675)	(2,573)
Net proceeds from issuance of common stock	5,865	0
Payment of withholding taxes related to stock-based employee compensation	(58)	0
Net Cash Provided by (Used in) Financing Activities	5,132	(2,573)
Net Decrease in Cash and Cash Equivalents	(3,281)	(13,508)
Cash and Cash Equivalents - Beginning of period	5,580	26,080
Cash and Cash Equivalents - End of period	2,299	12,572
Supplemental Disclosure of Cash Flows Information
Interest	620	842
Non-cash investing and financing activities:
2016 Accrued bonus awarded in equity	374	0
2015 Accrued bonus awarded in equity	0	474
Common stock issued for contingent purchase price payments	$ 1,175	$ 2,574

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (the “Company”) is a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue. The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2017 and results of operations and cash flows for the three and six months ended June 30, 2017 and 2016. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”). The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year. The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation. Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported. In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective June 30, 2016, the Company entered into a purchase agreement with BSN medical, Inc. (“BSN”) whereby the Company agreed to sell to BSN all of the Company’s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the sorbion product line pursuant to its distribution agreement with Sorbion GmbH & Co KG. The results of operations for the three and six months ended June 30, 2016 reflect the Company’s continuing operations. Three Months Ended June 30, Six Months Ended June 30, 2016 2016 Revenue, net of returns, allowances and discounts $ 1,023 $ 1,709 Cost of revenues 348 536 Gross profit 675 1,173 Selling, general and administrative 171 323 Income from discontinued operations, net of tax $ 504 $ 850 Non-cash amortization expense of $ 19,000 38,000 There were no assets and liabilities or operating results of discontinued operations as of or for the three and six month periods ended June 30, 2017. 3.3 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311 The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, “Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted. There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, “Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),” was issued in March 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, “Identifying Performance Obligations and Licensing,” issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, “Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients” provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The impact of this new standard will depend on the extent and nature of future changes to the terms of Company's share-based payment awards.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	2. Going Concern The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. As of June 30, 2017, the Company had a cash balance of approximately $ 2.3 11.2 8.0 135.5 Note 7- Debt 22,250,000 24,600,000 27,200,000 30,300,000 38.0 Management is evaluating all options to raise sufficient funds to meet its outstanding debt obligations and to fund the Company’s working capital requirements. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company. There is no assurance that the Company will be successful in achieving profitable operations. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	3. Net Loss Per Common Share Basic (loss) income per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted (loss) income per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock. Three Months Ended Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net (loss) income from continuing operations (numerator for basic and diluted earnings per share) $ (4,204) $ 1,357 $ (11,201) $ (6,671) Weighted average shares outstanding (denominator for basic earnings per share) 45,236,890 28,169,843 38,015,273 27,731,465 Effect of dilutive securities: Assumed vesting of restricted stock, treasury stock method - 398,757 - - Dilutive potential common shares - 398,757 - - Denominator for diluted earnings per share- weighted average shares and assumed potential common shares 45,236,890 28,568,600 38,015,273 27,731,465 Basic (loss) earnings from continuing operations per share $ (0.09) $ 0.05 $ (0.29) $ (0.24) Diluted (loss) earnings from continuing operations per share $ (0.09) $ 0.05 $ (0.29) $ (0.24) Three Months Ended Ended June 30, Six Months Ended Ended June 30, 2017 2016 2017 2016 Options 9,210,498 7,427,279 9,210,498 7,427,279 Warrants 5,171,672 3,365,407 5,171,672 3,365,407 Non-vested restricted stock 2,616,026 460,001 2,616,026 1,480,041 Total potentially dilutive shares 16,998,196 11,252,687 16,998,196 12,272,727

Termination of Merger Agreement

Termination of Merger Agreement	6 Months Ended
	Jun. 30, 2017
Disclosure Text Block Supplement [Abstract]
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	Termination of Merger Agreement On October 5, 2016, the Company entered into a merger agreement to acquire the business of Soluble Systems, LLC (“Soluble”) through a series of transactions. On February 27, 2017, the Company terminated this agreement, due to its inability to secure the requisite financing to meet the closing conditions of the merger agreement. In connection with the merger agreement to acquire the business of Soluble, the Company provided Soluble with bridge loans in the form of subordinated promissory notes totaling approximately $ 1.4 1.0 350,000 350,000 285,000 0

Inventory

Inventory	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Inventory June 30, December 31, 2017 2016 Raw materials $ 151 $ 135 Work in process 168 173 Finished goods 2,476 2,394 Less: Inventory reserve for excess and slow moving inventory (12) - Total $ 2,783 $ 2,702

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2017
Payables and Accruals [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	Accrued Expenses and Other Current Liabilities June 30, December 31, 2017 2016 Salaries, benefits and incentive compensation $ 1,486 $ 3,070 Milestone payment to licensor 1,000 1,000 Professional fees 499 692 Royalty fees 208 197 Deferred revenue 230 181 Other 153 146 Total accrued expenses and other current liabilities $ 3,576 $ 5,286

Debt

Debt	6 Months Ended
	Jun. 30, 2017
Debt Instruments [Abstract]
Long-term Debt [Text Block]	7. Debt Senior Secured Term Loan Facility On May 29, 2015, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $ 15.5 June 30, 2017 was 10.80 In connection with the Credit Agreement, the Company incurred approximately $ 1.3 64,000 72,000 128,000 144,000 In connection with the entry into the Credit Agreement, a five-year warrant (the “Warrant”) to purchase 750,000 0.001 5.5138 2.7 157,000 159,000 297,000 284,000 Fair Value Measurement As of June 30, 2017, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement as a result of the Company’s failure to achieve $ 22,250,000 24,600,000 27,200,000 30,300,000 13.8 The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the Warrant. The amended and restated Warrant, as amended, is exercisable for 2,100,000 0.47 Fair Value Measurement June 30, December 31, 2017 2016 Long-term debt $ 13,752 $ 13,752 Unamortized debt issuance and discount costs (1,786) (2,211) Total $ 11,966 $ 11,541

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Agreements for Human Placental Based Products Human Longevity, Inc. In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) and Supply Agreement (the “Biovance Supply Agreement”) with Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”). The agreements grant the Company an exclusive, royalty-bearing license in CCT’s intellectual property for certain placental based products, including ECM and Biovance ®, as well as provide the Company with the its requirements of Biovance for distribution. In January 2016, HLI Cellular Therapeutics, LLC (“HLI”), a genomics-based, technology-driven company, announced the purchase of LifebankUSA and other select assets from CCT. CCT assigned and HLI assumed the license and supply agreements the Company entered into with CCT, for certain placental based products. In June 2017, Celularity, Inc. (“Celularity”) acquired some of the assets of HLI, including the agreements between HLI and the Company. The Company is required to pay Celularity annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. For the three months ended June 30, 2017 and 2016, the Company incurred royalties of approximately $ 207,000 108,000 392,000 175,000 207,000 197,000 The License Agreement with Celularity is terminable on a product-by-product basis if the Company fails to meet certain minimum sales thresholds in the second year or any subsequent year of commercial sales of each licensed product. Each year of commercial sales are referred to in the License Agreement as “launch years” and the calendar period constituting each launch year for each licensed product is determined in accordance with the terms of the License Agreement. To maintain its license for Biovance, the Company must meet a minimum gross sales amount for Biovance in the second year and third year of commercial sales. If the Company fails to meet the minimum threshold in the second year of commercial sales of product, it would be able to cure such failure by making a cure payment specified in the License Agreement to Celularity; provided, however, the Company does not have the option to make a cure payment, should it fail to meet the minimum threshold for such product in the third year of commercial sales and Celularity may terminate the License Agreement with respect to such product. In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product, also known as Interfyl. In April 2016, the Company entered into a Supply Agreement with HLI, pursuant to which HLI supplies the Company with the Company’s entire requirement of Interfyl™ Human Connective Tissue Matrix. Additionally, the Company agreed to make certain future milestone payments upon the achievement of certain milestones. The Company initiated sales and marketing efforts of Interfyl™ Human Connective Tissue Matrix in September 2016 and achieved two milestones under the license agreement. The Company is required to pay Celularity $ 500,000 500,000 1.0 Contingent Consideration Celleration, Inc. On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds. The Company agreed to pay contingent consideration of 3.5 times revenue from acquired MIST Therapy products in excess of certain revenue targets for the years ending December 31, 2015 and 2016, payable in equal amounts of cash and the Company’s common stock. This contingent consideration was payable in two installments in March 2016 and March 2017. The first installment consisted of $ 2.6 986,000 2.6 3.5 10.2 8.7 The second installment consisted of $ 675,000 675,000 3.5 10.5 10.2 Choice Therapeutics, Inc. On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary TheraBond 3D® Antimicrobial Barrier Systems. The Company agreed to pay contingent consideration based upon the Company achieving specific performance metrics over the three twelve month periods, ended April 30, 2017. The Company issued approximately 1.3 500,000 Litigation, Claims and Assessments The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of June 30, 2017.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2017
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	9. Stockholders’ Equity Private Placement On February 27, 2017, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the “Private Placement”) an aggregate of 5,540,000 0.50 2.8 196,000 40,000 The Securities Purchase Agreement contains a “most-favored nation” provision that provides that if the Company, during 120 days from February 27, 2017, issues or sells any common stock or common stock equivalents reasonably believed to be more favorable in terms or conditions than those in the Private Placement, then the Company must amend the terms of the Securities Purchase Agreement to give the private investors the benefit of such favorable terms or conditions. In connection with the common stock sold in the Public Offering (as defined below) and in accordance with this provision, on April 11, 2017, the Company issued an aggregate of 380,717 1,004,283 Underwritten Public Offering On April 3, 2017, the Company closed an underwritten public offering (the “Public Offering”) of 9,473,250 0.40 3.8 365,000 92,000 On April 3, 2017, the Company issued warrants to purchase an aggregate of 236,831 0.44 March 29, 2022 78,000 Pursuant to an anti-dilution provision provided in the warrants dated November 8, 2012 to purchase common stock at an initial exercise price of $ 2.19 0.40 362,293 Stock-Based Compensation For the three months ended June 30, 2017 and 2016, the Company recognized $ 427,000 1.4 15,000 47,000 412,000 1.3 918,000 3.1 26,000 129,000 892,000 3.0 2.2 0.9 Stock Options On June 27, 2017, the Company granted non-executive employees ten-year options to purchase an aggregate of 2,080,500 0.35 519,000 Restricted Stock During the six months ended June 30, 2017, the Company granted an aggregate of 1,819,358 621,000 669,358 50,000 500,000 600,000

Related Party

Related Party	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Related Party In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director was then member of the Board of Directors. During the three months ended June 30, 2017 and 2016, the Company incurred costs of approximately $ 131,000 53,000 258,000 99,000 102,000

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	11. Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Warrant Liabilities The Company amended and restated the Warrant on each of October 25, 2016, January 26, 2017, March 7, 2017 and April 6, 2017. In addition, on June 1, 2017, the Company further amended the amended and restated Warrant. The amended and restated Warrant, as amended, is exercisable for 2,100,000 0.47 Debt 65.33 78.98 1.49 1.95 3.34 5.00 0.00 33,000 803,000 On June 30, 2017, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 2,462,293 454,000 75.79 89.28 1.03 1.89 0.36 4.58 0.00 369,000 5.51 0.50 0.40 66,287 290,338 362,293 Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer. Six Months Ended June 30, 2017 2016 Warrant Liabilities Beginning balance $ 20 $ 861 Change in fair value of warrant liability (369) (662) Warrant modification expense 803 - Ending balance $ 454 $ 199 Six Months Ended June 30, 2017 2016 Contingent Consideration Beginning balance $ 1,816 $ 17,028 Payments of contingent consideration (1,851) (5,147) Change in fair value of contingent consideration 35 (8,730) Ending balance $ - $ 3,151 June 30, 2017 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 454 Contingent consideration - - - Total liabilities $ - $ - $ 454 December 31, 2016 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 20 Contingent consideration - - 1,816 Total liabilities $ - $ - $ 1,836

Description of Business and B18

Description of Business and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2017 and results of operations and cash flows for the three and six months ended June 30, 2017 and 2016. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 (the “2016 Annual Report”). The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective June 30, 2016, the Company entered into a purchase agreement with BSN medical, Inc. (“BSN”) whereby the Company agreed to sell to BSN all of the Company’s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights to the sorbion product line pursuant to its distribution agreement with Sorbion GmbH & Co KG. The results of operations for the three and six months ended June 30, 2016 reflect the Company’s continuing operations. Three Months Ended June 30, Six Months Ended June 30, 2016 2016 Revenue, net of returns, allowances and discounts $ 1,023 $ 1,709 Cost of revenues 348 536 Gross profit 675 1,173 Selling, general and administrative 171 323 Income from discontinued operations, net of tax $ 504 $ 850 Non-cash amortization expense of $ 19,000 38,000 There were no assets and liabilities or operating results of discontinued operations as of or for the three and six month periods ended June 30, 2017.
Asset Sale [Policy Text Block]	Asset Sale 3.3 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311
Significant Accounting Policies and Estimates [Policy Text Block]	Significant Accounting Policies and Estimates The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Principles In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, “Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted. There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, “Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),” was issued in March 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, “Identifying Performance Obligations and Licensing,” issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, “Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients” provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting (“ASU 2017-09”). This ASU clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The standard is effective for the Company on January 1, 2018, with early adoption permitted. The impact of this new standard will depend on the extent and nature of future changes to the terms of Company's share-based payment awards.

Description of Business and B19

Description of Business and Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2017
Disposal Groups, Including Discontinued Operations [Table Text Block]	Summarized operating results of discontinued operations for the three and six months ended June 30, 2016 are presented in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2016 Revenue, net of returns, allowances and discounts $ 1,023 $ 1,709 Cost of revenues 348 536 Gross profit 675 1,173 Selling, general and administrative 171 323 Income from discontinued operations, net of tax $ 504 $ 850
Schedule of Gain Loss on Disposal of Discontinued Operations [Table Text Block]	During the three and six months ended June 30, 2016, the Company recorded a gain of approximately $ 3.3 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The Company calculated the potential diluted (loss) earnings per share in accordance with ASC 260, as follows (in thousands, except per share amounts): Three Months Ended Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net (loss) income from continuing operations (numerator for basic and diluted earnings per share) $ (4,204) $ 1,357 $ (11,201) $ (6,671) Weighted average shares outstanding (denominator for basic earnings per share) 45,236,890 28,169,843 38,015,273 27,731,465 Effect of dilutive securities: Assumed vesting of restricted stock, treasury stock method - 398,757 - - Dilutive potential common shares - 398,757 - - Denominator for diluted earnings per share- weighted average shares and assumed potential common shares 45,236,890 28,568,600 38,015,273 27,731,465 Basic (loss) earnings from continuing operations per share $ (0.09) $ 0.05 $ (0.29) $ (0.24) Diluted (loss) earnings from continuing operations per share $ (0.09) $ 0.05 $ (0.29) $ (0.24)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Three Months Ended Ended June 30, Six Months Ended Ended June 30, 2017 2016 2017 2016 Options 9,210,498 7,427,279 9,210,498 7,427,279 Warrants 5,171,672 3,365,407 5,171,672 3,365,407 Non-vested restricted stock 2,616,026 460,001 2,616,026 1,480,041 Total potentially dilutive shares 16,998,196 11,252,687 16,998,196 12,272,727

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following (in thousands): June 30, December 31, 2017 2016 Raw materials $ 151 $ 135 Work in process 168 173 Finished goods 2,476 2,394 Less: Inventory reserve for excess and slow moving inventory (12) - Total $ 2,783 $ 2,702

Accrued Expenses and Other Cu22

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	June 30, December 31, 2017 2016 Salaries, benefits and incentive compensation $ 1,486 $ 3,070 Milestone payment to licensor 1,000 1,000 Professional fees 499 692 Royalty fees 208 197 Deferred revenue 230 181 Other 153 146 Total accrued expenses and other current liabilities $ 3,576 $ 5,286

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Instruments [Abstract]
Schedule of Debt [Table Text Block]	Debt consists of the following (in thousands): June 30, December 31, 2017 2016 Long-term debt $ 13,752 $ 13,752 Unamortized debt issuance and discount costs (1,786) (2,211) Total $ 11,966 $ 11,541

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): Six Months Ended June 30, 2017 2016 Warrant Liabilities Beginning balance $ 20 $ 861 Change in fair value of warrant liability (369) (662) Warrant modification expense 803 - Ending balance $ 454 $ 199 Six Months Ended June 30, 2017 2016 Contingent Consideration Beginning balance $ 1,816 $ 17,028 Payments of contingent consideration (1,851) (5,147) Change in fair value of contingent consideration 35 (8,730) Ending balance $ - $ 3,151
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands): June 30, 2017 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 454 Contingent consideration - - - Total liabilities $ - $ - $ 454 December 31, 2016 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 20 Contingent consideration - - 1,816 Total liabilities $ - $ - $ 1,836

Description of Business and B25

Description of Business and Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue, net of returns, allowances and discounts		$ 1,023		$ 1,709
Cost of revenues		348		536
Gross profit		675		1,173
Selling, general and administrative		171		323
Income from discontinued operations, net of tax	$ 0	$ 504	$ 0	$ 850

Description of Business and B26

Description of Business and Basis of Presentation (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Proceeds from sale
Consideration for inventory				$ 603
Consideration for intangible assets				3,500
Total Consideration				4,103
Less: Net book value of assets sold to BSN
Inventory, net		$ (603)		(603)
Intangibles, net		(189)		(189)
Total net book value of assets		(792)		(792)
Gain on sale of assets	$ 0	$ 3,311	$ 0	$ 3,311

Description of Business and B27

Description of Business and Basis of Presentation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	$ 0	$ 3,311,000	$ 0	$ 3,311,000
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	$ 0	0	$ 0	0
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax		3.3		3.3
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of Intangible Assets		$ 19,000		$ 38,000

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Net Income (Loss) Attributable to Parent, Total	$ (4,204,000)	$ 5,172,000	$ (11,201,000)	$ (2,510,000)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total			(7,984,000)	(10,451,000)
Retained Earnings (Accumulated Deficit), Total	(135,504,000)		(135,504,000)		$ (135,504,000)		$ (124,303,000)
Cash and Cash Equivalents, at Carrying Value, Total	2,299,000	$ 12,572,000	2,299,000	$ 12,572,000	2,299,000		5,580,000		$ 26,080,000
Intangible Assets, Net (Including Goodwill)	$ 38,000,000		$ 38,000,000		38,000,000
Gross Revenue					$ 30,300,000	$ 27,200,000	$ 24,600,000	$ 22,250,000

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator:
Net (loss) income from continuing operations (numerator for basic and diluted earnings per share)	$ (4,204)	$ 1,357	$ (11,201)	$ (6,671)
Weighted average shares outstanding (denominator for basic earnings per share)	45,236,890	28,169,843	38,015,273	27,731,465
Effect of dilutive securities:
Assumed vesting of restricted stock, treasury stock method	0	398,757,000	0	0
Dilutive potential common shares	0	398,757,000	0	0
Denominator for diluted earnings per share- weighted average shares and assumed potential common shares	45,236,890	28,568,600	38,015,273	27,731,465
Basic (loss) earnings from continuing operations per share	$ (0.09)	$ 0.05	$ (0.29)	$ (0.24)
Diluted (loss) earnings from continuing operations per share	$ (0.09)	$ 0.05	$ (0.29)	$ (0.24)

Net Loss Per Common Share (De30

Net Loss Per Common Share (Details 1) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	16,998,196	11,252,687	16,998,196	12,272,727
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,210,498	7,427,279	9,210,498	7,427,279
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,171,672	3,365,407	5,171,672	3,365,407
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,616,026	460,001	2,616,026	1,480,041

Termination of Merger Agreeme31

Termination of Merger Agreement (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jan. 30, 2017	Dec. 31, 2016	Oct. 05, 2016
Long-term Debt, Gross	$ 13,752,000		$ 13,752,000			$ 13,752,000
Provision for Doubtful Accounts			75,000	$ 31,000
Business Combination, Acquisition Related Costs	0	$ 104,000	635,000	$ 104,000
Bridge Loan [Member]
Long-term Debt, Gross							$ 1,400,000
Debt Instrument, Face Amount					$ 350,000	1,000,000
Provision for Doubtful Accounts			350,000
Business Combination, Acquisition Related Costs			285,000
Prepaid Expenses and Other Current Assets [Member]
Notes Receivable, Current	$ 0		$ 0			$ 0

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory [Line Items]
Raw materials	$ 151	$ 135
Work in process	168	173
Finished goods	2,476	2,394
Less: Inventory reserve for excess and slow moving inventory	(12)	0
Total	$ 2,783	$ 2,702

Accrued Expenses and Other Cu33

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 1,486	$ 3,070
Milestone payment to licensor	1,000	1,000
Professional fees	499	692
Royalty fees	208	197
Deferred revenue	230	181
Other	153	146
Total accrued expenses and other current liabilities	$ 3,576	$ 5,286

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-term debt	$ 13,752	$ 13,752
Unamortized debt issuance and discount costs	(1,786)	(2,211)
Total	$ 11,966	$ 11,541

Debt (Details Textual)

Debt (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 01, 2017	Dec. 31, 2015	May 29, 2015	Nov. 30, 2012
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									2,100,000
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001		$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.5138		$ 5.5138		$ 5.5138				$ 0.47			$ 5.51
Derivative Liability	$ 454,000	$ 199,000	$ 454,000	$ 199,000	$ 454,000		$ 20,000			$ 861,000
Amortization of Debt Discount (Premium)			$ 425,000	428,000
Common Stock Purchased By Warrants Issued			750,000
Exit fee payment, Credit Agreement Description			The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000, which was amended in conjunction with the extinguishment of debt described below from the greater of 1% of the outstanding principal balance immediately prior to the final payment or $100,000.
Revenues	5,522,000	4,467,000	$ 10,116,000	8,424,000
Long-term Debt, Gross	13,752,000		13,752,000		13,752,000		13,752,000
Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability	454,000		454,000		454,000		20,000
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability	2,700,000		2,700,000		2,700,000
Interest Expense [Member]
Debt Instrument [Line Items]
Amortization of Financing Costs	64,000	72,000	128,000	144,000
Amortization of Debt Discount (Premium)	157,000	$ 159,000	297,000	$ 284,000
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											$ 15,500,000
Debt Issuance Costs1			$ 1,300,000
Debt Instrument, Interest Rate Terms			accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%
Debt Instrument, Payment Terms			is interest only until June 30, 2017, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date
Debt Instrument, Maturity Date, Description			The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000
Debt Instrument, Interest Rate During Period			10.80%
Long-term Debt, Gross	$ 13,800,000		$ 13,800,000		13,800,000		13,800,000
Credit Agreement [Member]
Debt Instrument [Line Items]
Revenues					$ 30,300,000	$ 27,200,000	$ 24,600,000	$ 22,250,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Royalty Expense	$ 209,000		$ 258,000		$ 394,000	$ 475,000
Accrued Liabilities, Current	3,576,000				3,576,000		$ 5,286,000
Payments to Acquire Businesses, Gross					675,000	2,573,000
Revenues	5,522,000		4,467,000		10,116,000	8,424,000
Installment One [Member] | Two Thousand Fifteen MIST Therapy [Member]
Commitments And Contingencies [Line Items]
Revenues				$ 10,200,000
Installment One [Member] | Two Thousand Fourteen MIST Therapy [Member]
Commitments And Contingencies [Line Items]
Revenues				$ 8,700,000
Installment two [Member]
Commitments And Contingencies [Line Items]
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets		3.5
Payments to Acquire Businesses, Gross		$ 675,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned		675,000
Installment two [Member] | Two Thousand Fifteen MIST Therapy [Member]
Commitments And Contingencies [Line Items]
Revenues		10,200,000
Installment two [Member] | Two Thousand Sixteen MIST Therapy [Member]
Commitments And Contingencies [Line Items]
Revenues		$ 10,500,000
Human Longevity, Inc [Member]
Commitments And Contingencies [Line Items]
Royalty Expense	207,000		108,000		392,000	175,000
Accrued Liabilities, Current	207,000		$ 197,000		207,000	$ 197,000
Revenue Recognition, Milestone Method, Milestone Expenses					1,000,000
Human Longevity, Inc [Member] | First Commercial Sale [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months	500,000				500,000
Human Longevity, Inc [Member] | Second Commercial Sale [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months	500,000				500,000
Choice Therapeutics, Inc. [Member]
Commitments And Contingencies [Line Items]
Business Combination, Contingent Consideration, Liability	$ 500,000				$ 500,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares					1,300,000
Contingent Consideration [Member] | Installment One [Member]
Commitments And Contingencies [Line Items]
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets				3.5
Payments to Acquire Businesses, Gross				$ 2,600,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares				986,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned				$ 2,600,000

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)

Apr. 11, 2017

Apr. 03, 2017

Jun. 27, 2017

Feb. 27, 2017

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Jun. 23, 2017

Jun. 01, 2017

Dec. 31, 2016

Dec. 31, 2015

Nov. 30, 2012

Nov. 08, 2012

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 427,000

$ 1,400,000

$ 918,000

$ 3,100,000

Proceeds from Issuance of Private Placement

$ 2,800,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

2,100,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.5138

$ 5.5138

$ 0.47

$ 5.51

Derivative Liability

$ 454,000

199,000

$ 454,000

199,000

$ 20,000

$ 861,000

Cost of Sales [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

15,000

47,000

26,000

129,000,000,000

Selling, General and Administrative Expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

412,000

$ 1,300,000

$ 892,000

$ 3,000,000

Private Placement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, New Issues

5,540,000

Share Price

$ 0.50

Payments for Other Fees

$ 196,000

Payment for Administrative Fees

$ 40,000

Underwritten Public Offering [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, New Issues

9,473,250

Share Price

$ 0.40

$ 0.40

Payments for Other Fees

$ 365,000

Payment for Administrative Fees

92,000

Stock Issued During Period, Value, New Issues

$ 3,800,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

236,831

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.44

$ 2.19

Class of Warrant or Right, Expiration Date

Mar. 29, 2022

Securities Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Issued During Period, Shares, New Issues

380,717

Securities Purchase Agreement [Member] | Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance

1,004,283

Non Executive Employees [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

2 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Non Executive Employees [Member] | Underwritten Public Offering [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,080,500

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.35

Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value

$ 519,000

Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

621,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value

$ 1,819,358

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total

$ 2,200,000

$ 2,200,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

10 months 24 days

Restricted Stock [Member] | Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

669,358

Restricted Stock [Member] | Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

50,000

Restricted Stock [Member] | Share-based Compensation Award, Tranche Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

500,000

Restricted Stock [Member] | Deferred Compensation, Share-based Payments [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

600,000

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Derivative Liability

$ 78,000

Related Party (Details Textual)

Related Party (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 131,000	$ 53,000	$ 258,000	$ 258,000
Accounts Payable, Related Parties	$ 99,000		$ 99,000		$ 102,000

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance			$ 20	$ 861
Change in fair value of warrant liability			(369)	(662)
Warrant modification expense	$ 33	$ 0	803	0
Ending balance	454	199	454	199
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance			1,816	17,028
Payments of contingent consideration			(1,851)	(5,147)
Change in fair value of warrant liability			35	(8,730)
Ending balance	$ 0	$ 3,151	$ 0	$ 3,151

Fair Value Measurement (Detai40

Fair Value Measurement (Details 1) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Liabilities:
Warrant liabilities	$ 454	$ 20	$ 199	$ 861
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	454	20
Contingent consideration	0	1,816
Total liabilities	$ 454	$ 1,836

Fair Value Measurement (Detai41

Fair Value Measurement (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 26, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 01, 2017	Dec. 31, 2016	Dec. 31, 2015	Nov. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability		$ 454	$ 199	$ 454	$ 199		$ 20	$ 861
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.5138		$ 5.5138		$ 0.47			$ 5.51
Fair Value Adjustment of Warrants		$ (251)	75	$ (369)	(662)
Restructuring Costs		33	$ 0	$ 803	$ 0
Class of Warrant or Right, Outstanding									66,287
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						2,100,000
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants To Purchase Common Stock				2,462,293
Maximum [Member] | Private Placement 2017 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.40
Class of Warrant or Right, Outstanding									362,293
Minimum [Member] | Private Placement 2017 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.50
Class of Warrant or Right, Outstanding									290,338
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability		$ 454		$ 454			$ 20
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Dividend Rate	0.00%			0.00%
Fair Value, Inputs, Level 3 [Member] | Maximum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate	78.98%			89.28%
Fair Value Assumptions, Risk Free Interest Rate	1.95%			1.89%
Fair Value Assumptions, Expected Term	5 years			4 years 6 months 29 days
Fair Value, Inputs, Level 3 [Member] | Minimum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate	65.33%			75.79%
Fair Value Assumptions, Risk Free Interest Rate	1.49%			1.03%
Fair Value Assumptions, Expected Term	3 years 4 months 2 days			4 months 10 days